financetom
Business
financetom
/
Business
/
BRIEF-Lyell Immunopharma To Acquire Immpact Bio And Prioritizes Its Pipeline To Focus On Next-Generation CAR T-cell Therapies
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Lyell Immunopharma To Acquire Immpact Bio And Prioritizes Its Pipeline To Focus On Next-Generation CAR T-cell Therapies
Nov 3, 2024 11:15 AM

Oct 24 (Reuters) - Lyell Immunopharma Inc ( LYEL ):

* LYELL IMMUNOPHARMA TO ACQUIRE IMMPACT BIO AND PRIORITIZES

ITS

PIPELINE TO FOCUS ON NEXT-GENERATION CAR T-CELL THERAPIES

* LYELL IMMUNOPHARMA INC ( LYEL ): IS DISCONTINUING DEVELOPMENT OF

LYL797,

LYL845 AND EARLIER-STAGE TIL PROGRAMS

Source text for Eikon:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved